Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
Olmesartan Medoxomil in Atherosclerosis
- Conditions
- Essential HypertensionAtherosclerotic Cardiovascular Disease
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-12-14
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 165
- Registration Number
- NCT00185185
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT00185068
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 125
- Registration Number
- NCT00171054
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 64
- Registration Number
- NCT00171132
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 583
- Registration Number
- NCT00153049
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Taya-gun, Gunma, Japan
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
- Conditions
- Essential Hypertension
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 174
- Registration Number
- NCT00157963
Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome
- Conditions
- Metabolic SyndromeHypertension
- Interventions
- First Posted Date
- 2005-05-10
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT00110422
- Locations
- 🇪🇸
Local Institution, Zaragoza, Spain
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 496
- Registration Number
- NCT00095550
- Locations
- 🇷🇺
Local Institution, St. Petersburg, Russian Federation
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)
- Conditions
- Hypertension
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 840
- Registration Number
- NCT00092209
Genetic Epidemiology of Responses to Antihypertensives
- Conditions
- HypertensionCardiovascular DiseasesHeart Diseases
- Interventions
- First Posted Date
- 2000-05-26
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1200
- Registration Number
- NCT00005520
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.